ERBB2 and carcinoma: Especially in aggressive breast cancer subtypes, such as triple negative and HER2 enriched carcinomas, pCR is a suitable surrogate end point, however, pCR is not a reliable marker for endpoint in luminal B HER2− or luminal A tumors13.